![学納金サイト [在学生・保護者専用]](/assets/images/BlkFeatured_item_tuition.jpg)
Faculty of Medicine教員紹介：福原 浩
| 氏名 |
福原 浩
フクハラ ヒロシ FUKUHARA, Hiroshi |
|---|---|
| 職位 | 教授 |
| 学内の役職・委員等 | 教授 |
| 所属教室 | |
| 専攻・専門分野（大学院） |
医学専攻 泌尿器科学分野（新課程） 外科系専攻 泌尿器科学分野（旧課程） |
| 担当科目（学部） | 泌尿器科学 |
| 担当科目（大学院） | 泌尿器科学演習、泌尿器腫瘍学 |
| 専門分野 | 泌尿器腫瘍学、腹腔鏡・ロボット手術、ウイルス療法 |
| 研究テーマ | 1.がん治療用ウイルスを用いたウイルス療法 2.泌尿器癌におけるがんゲノム医療 |
| 略歴 | 1995年 東京大学医学部医学科卒業 2001年 米国ハーバード大学(MGH病院) フェロー 2006年 東京大学医学部泌尿器科 講師 2014年 東京大学大学院医学系研究科泌尿器外科 准教授 2018年 杏林大学医学部泌尿器科 教授 |
| 所有する学位 | 博士（医学） |
| 指導医・専門医・認定医、その他の資格等 | 日本泌尿器科学会：専門医・指導医、泌尿器腹腔鏡技術認定医、日本内視鏡外科学会技術認定医、癌治療認定医、腹腔鏡下小切開手術施設基準医認定医、泌尿器ロボット支援手術プロクター認定医 |
| 論文・著書等を含む主要研究業績 |
2023年 1. Fukuhara H, Sato YT, Hou J, Iwai M, Todo T. Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12. Commun Med (Lond). 3, 40, 2023. 2. Kinjo M, Masuda K, Nakamura Y, Miyakawa J, Tambo M, Fukuhara H. Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study. Urology. 2023, in press. 3. Kinjo M, Masuda K, Nakamura Y, Taguchi S, Tambo M, Fukuhara H. Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder? Int Urogynecol J. 34, 853-859, 2023. 4. Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab. Immunotherapy, 2023, in press. 5. Iwaki T, Akiyama Y, Nosato H, Kinjo M, Niimi A, Taguchi S, Yamada Y, Sato Y, Kawai T, Yamada D, Sakanashi H, Kume H, Homma Y, Fukuhara H. Deep Learning Models for Cystoscopic Recognition of Hunner Lesion in Interstitial Cystitis. Eur Urol Open Sci. 49, 44-50, 2023. 6. Ochiai K, Mochida Y, Nagase T, Fukuhara H, Ymaguchi Y, Nagase M. Upregulation of piezo2 in the mesangial, renin, and perivascular mesenchymal cells of the kidney of Dahl salt-sensitive hypertensive rats and its reversal by esaxerenone. Hypertens Res. 2023, in press. 2022年 7. Sugimoto K, Taguchi S, Kishitani K, Kawai T, Masuda K, Nakamura Y, Kinjo M, Tambo M, Miyakawa J, Akiyama Y, Yamada Y, Sato Y, Yamada D, Nakagawa T, Fukuhara H, Kume H. Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma. BMC Urol. 22, 177, 2022. 8. Taguchi S, Kawai T, Nakagawa T, Miyakawa J, Kishitani K, Sugimoto K, Nakamura Y, Kamei J, Obinata D, Yamaguchi K, Kaneko T, Yoshida K, Yamamoto S, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Matsumoto A, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Ishikawa A, Tanaka Y, Nagase Y, Fujimura T, Fukuhara H, Takahashi S, Kume H. Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020). Int J Urol. 29, 1462-1469, 2022. 9. Kinjo M, Masuda K, Nakamura Y, Taguchi S, Tambo M, Fukuhara H. Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder? Int Urogynecol J. 2022, in press. 10. Taguchi S, Watanabe M, Tambo M, Machida H, Yokoyama K, Fukuhara H. Proposal for a New Vesical Imaging-Reporting and Data System (VI-RADS)-Based Algorithm for the Management of Bladder Cancer: A Paradigm Shift From the Current Transurethral Resection of Bladder Tumor (TURBT)-Dependent Practice. Clin Genitourin Cancer. 20, e291-e295, 2022. 11. Nakamura Y, Taguchi S, Kinjo M, Tanbo M, Okegawa T, Fukuhara H. Adrenal metastasis in nivolumab-treated renal cell carcinoma: A unique entity as a sanctuary site. Int. J Urol. 29, 597-599, 2022. 12. Kinjo M, Tanba M, Masuda K, Nakamura Y, Tanbo M, Fukuhara H. Comparison of effectiveness between modified transvaginal mesh surgery and vaginal pessary treatment in patients with symptomatic pelvic organ prolapse. Low Urin Tract Symptoms. 14, 64-71, 2022. 13. Shishido T, Okegawa T, Hayashi K, Masuda K, Taguchi S, Nakamura Y, Tambo M, Fukuhara H. Laparoscopic retroperitoneal lymph node dissection versus open retroperitoneal lymph node dissection for testicular cancer: A comparison of clinical and perioperative outcomes. Asian J Urol, 9, 119-124, 2022. 14. Kitahama K, Yoshiike S, Nagahama K, Ninomiya N, Okegawa T, Fukuhara H, Nabeshima K, Oka T, Shibahara J. Well-differentiated papillary mesothelial tumor presenting as an encysted hydrocele of the spermatic cord. Pathol Int. 72, 352-354, 2022. 15. Watanabe M, Taguchi S, Machida H, Tambo M, Takeshita Y, Kariyasu T, Fukushima K, Shimizu Y, Okegawa T, Fukuhara H, Yokoyama K. Clinical validity of non-contrast-enhanced VI-RADS: prospective study using 3-T MRI with high-gradient magnetic field. Eur Radiol. 32, 7513-7521, 2022. 16. Mochida Y, Ochiai K, Nagase T, Nonomura K, Akimoto Y, Fukuhara H, Sakai T, Matsumura G, Yamaguchi Y, Nagase M. Piezo2 expression and its alteration by mechanical forces in mouse mesangial cells and renin-producing cells. Sci Rep. 12, 4197, 2022. 17. Kato T, Yokomizo A, Matsumoto R, Tohi Y, Miyakawa J, Mitsuzuka K, Sasaki H, Inokuchi J, Matsumura M, Sakamoto S, Kinoshita H, Fukuhara H, Kamiya N, Kimura R, Nitta M, Okuno H, Akakura K, Kakehi Y, Sugimoto M. Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS-JAPAN study. Int J Urol. 29, 1271-1278, 2022. 18. Kawai T, Taguchi S, Nakagawa T, Kamei J, Nakamura Y, Obinata D, Yamaguchi K, Kaneko T, Kakutani S, Tokunaga M, Uemura Y, Sato Y, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Takahashi S, Kume H. Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis. J Immunother Cancer. 10, e003965, 2022. 19. Tohi Y, Kato T, Miyakawa J, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Matsumura M, Yokomizo A, Kinoshita H, Hara I, Kawamura N, Hashimoto K, Inoue M, Teishima J, Kanno H, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Kakehi Y, Sugimoto M. Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study. Jpn J Clin Oncol. 52, 1056-1061, 2022. 20. Yokomizo A, Yonese J, Egawa S, Fukuhara H, Uemura H, Nishimura K, Nagata M, Saito A, Lee T, Yamaguchi S, Nonomura N. Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan. Int J Clin Oncol. 27, 418-426, 2022. 21. Tohi Y, Kato T, Nakamura M, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Hashine K, Yokomizo A, Naito H, Hara I, Kawamura N, Inoue M, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Egawa S, Kakehi Y, Sugimoto M. Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study. Int J Clin Oncol. 27, 194-201, 2022. 22. Oshina T, Taguchi S, Miyakawa J, Akiyama Y, Sato Y, Kawai T, Fukuhara H, Nakagawa T, Kume H. Clinicopathological features and oncological outcomes of urothelial carcinoma involving the ureterovesical junction. Jpn J Clin Oncol. 52, 65-72, 2022. 23. Tohi Y, Kato T, Yokomizo A, Mitsuzuka K, Tomida R, Inokuchi J, Matsumoto R, Saito T, Sasaki H, Inoue K, Kinoshita H, Fukuhara H, Maruyama S, Sakamoto S, Tanikawa T, Egawa S, Ichikura H, Abe T, Nakamura M, Kakehi Y, Sugimoto M. Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer; results from a prospective cohort in the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study. Urol Oncol. 40, 56.e.9-e15, 2022. 24. Kato T, Hirama H, Mitsuzuka K, Maruyama S, Sasaki H, Saito T, Matsumoto R, Sakamoto S, Sakai Y, Fukuhara H, Naya Y, Tsukino H, Hara I, Ogawa O, Hashine K, Fumimasa F, Yokomizo A, Tohi Y, Kakehi Y, Sugimoto M. Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN. Prostate Cancer Prostatic Dis. 25, 666-671, 2022. 2021年 25. Fukuhara H, Takeshima Y, Todo T. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumor. Cancer Sci, 112, 3293-3301, 2021. 26. Higashihara E, Nutahara K, Itoh M, Okegawa T, Tambo M, Yamaguchi T, Nakamura Y, Taguchi S, Kaname S, Yokoyama K, Yoshioka T, Fukuhara H. Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD. Kidney Int Rep. 7, 270-281, 2021. 27. Kitamura J, Taguchi S, Okegawa T, Honda K, Kii T, Tomida Y, Matsumoto R, Ninomiya N, Masuda K, Nakamura Y, Yamaguchi T, Kinjo M, Tambo M, Isomura A, Hayashi A, Kamma H, Higashihara E, Shibahara J, Fukuhara H. Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report. BMC Med Genomics. 14, 217, 2021 28. Taguchi S, Kawai T, Nakagawa T, Nakamura Y, Kamei J, Obinata D, Yamaguchi K, Kaneko T, Kakutani S, Tokunaga M, Uemura Y, Sato Y, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Takahashi S, Kume H. Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study. Sci Rep. 11, 15623, 2021. 29. Shigemori K, Higashihara E, Itoh M, Yoshida H, Yamamoto K, Nutahara K, Shiokawa Y, Kaname S, Tambo M, Yamaguchi T, Taguchi S, Yoshioka T, Yokoyama K, Fukuhara H. PKD1- associated Arachnoid Cysts in Autosomal Dominant Polycystic Kidney Disease. J Stroke Cerebrovasc Dis. 30, 105943, 2021. 30. Kii T, Taguchi S, Nagahama K, Shimoyamada H, Honda K, Tomida Y, Matsumoto R, Kitamura J, Ninomiya N, Masuda K, Nakamura Y, Yamaguchi T, Kinjo M, Tambo M, Okegawa T, Higashihara E, Shibahara J, Fukuhara H. Pigmented median raphe cyst of the penis that developed after middle age without infection or trauma history. IJU Case Reports, 4, 172-175, 2021. 31. Taguchi S, Morikawa T, Shibahara J, Fukuhara H. Prognostic significance of tertiary Gleason pattern in the contemporary era of Gleason grade grouping: A narrative review. Int J Urol. 28, 614-621, 2021. 32. Taguchi S, Nakagawa T, Uemura Y, Akamatsu N, Gonoi W, Naito A, Kawai T, Kume H, Fukuhara H. Comparison of Major Definitions of Sarcopenia Based on the Skeletal Muscle Index in Patients with Urothelial Carcinoma. Future Oncology, 17, 197-203, 2021. 33. Taguchi S, Tambo M, Watanabe M, Machida H, Kariyasu T, Fukushima K, Shimizu Y, Okegawa T, Yokoyama K, Fukuhara H. Prospective validation of Vesical Imaging-Reporting and Data System (VI-RADS) using a next-generation magnetic resonance imaging scanner: Is denoising deep learning reconstruction useful? J Urol, 205. 686-692, 2021. 34. Kinjo M, Nakamura Y, Taguchi S, Yamaguchi T, Tambo M, Okegawa T, Fukuhara H. Sex differences in prevalence and patient behavior regarding lower urinary tract symptoms among Japanese medical checkup examinees. Urology, 151, 24-30, 2021. 35. Uchihashi T, Nakahara H, Fukuhara H, Iwai M, Ito H, Sugauchi A, Tanaka M, Kogo M, Todo T. Oncolytic herpes virus G47∆ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis, Mol Ther Oncolytics. 22, 388-398, 2021. 36. Matsumura S, Nakamori M, Tsuji T, Kato T, Nakamura M, Ojima T, Fukuhara H, Ino Y, Todo T, Yamaue H. Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer. Oncotarget, 12, 344-354, 2021. 37. Inoue T, Okada S, Hamamoto S, Miura H, Matsuzaki J, Tambo M, Fukuhara H, Fujisawa M, Matsuda T, Nutahara K. Evaluation of flexible ureteroscope with an omni-directional bending tip, using a JOYSTICK unit (URF-Y0016); an ex-vivo study. World Journal of Urology, 39, 209-215, 2021. 38. Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S. Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer. Clin Cancer Res. 27, 6164-6173, 2021. 2020年 39. Higashihara E, Horie S, Muto S, Kawano H, Tanbo M, Yamaguchi T, Taguchi S, Kaname S, Yokoyama K, Yoshioka T, Fukukawa T, Fukuhara H. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan. American Journal of Nephrology, 51, 891-890, 2020. 40. Kinjo M, Masuda K, Nakamura Y, Taguchi S, Tambo M, Okegawa T, Fukuhara H. Effects on depression and anxiety after mid-urethral sling surgery for female stress urinary incontinence. Research and Reports in Urology, 12, 495-501, 2020. 41. Higashihara E, Fukuhara H, Ouyang J, Lee J, Nutahara K, Tanbo M, Yamaguchi T, Taguchi S, Muto S, Kanayama S, Miyazaki I, Horie S. Estimation of changes in kidney volume growth rate in autosomal dominant polycystic kidney disease. Kidney Int Rep., 5, 1459-1471, 2020. 42. Omura S, Taguchi S, Miyagawa S, Matsumoto R, Samejima M, Ninomiya N, Masuda K, Nakamura Y, Yamaguchi T, Kinjo M, Tambo M, Okegawa T, Higashihara E, Fukuhara H. Prognostic significance of the albumin-to-globulin ratio for upper tract urothelial carcinoma. BMC Urology, 20, 133, 2020. 43. Naito A, Taguchi S, Suzuki M, Kawai T, Uchida K, Fujimura T, Fukuhara H, Kume H. Transient acute kidney injury observed immediately after robot-assisted radical prostatectomy but not after open radical prostatectomy. Molecular and Clinical Oncology, 13, 18, 2020. 44. Taguchi S, Shiraishi K, Fukuhara H. Updated evidence on oncological outcomes of surgery versus external beam radiotherapy for localized prostate cancer. Jpn J Clin Oncol. 50, 963-969, 2020. 45. Taguchi S, Uemura Y, Fujimura T, Morikawa T, Naito A, Kawai T, Suzuki M, Kume H, Fukuhara H. Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: development of the modified Gleason grade grouping (mGGG) model. BMC Cancer, 20, 371, 2020. 46. Okegawa T, Omura S, Samejima M, Ninomiya N, Taguchi S, Nakamura Y, Yamaguchi T, Tambo M, Fukuhara H. Laparoscopic radical prostatectomy versus robot-assisted radical prostatectomy: comparison of oncological outcomes at a single center. Prostate Int. 8, 16-21, 2020. 47. Tambo M, Taguchi S, Nakamura Y, Okegawa T, Fukuhara H. Presepsin and procalcitonin as predictors of sepsis based on the new Sepsis-3 definition in obstructive pyelonephritis. BMC Urol. 20, 23, 2020. 48. Masuda K, Aizawa N, Watanabe D, Okegawa T, Kume H, Igawa Y, Fukuhara H. Pathophysiological changes of the lower urinary tract behind voiding dysfunction in streptozotocin-induced long-term diabetic rats. Scientific Reports. 10, 4182, 2020. 49. Kakutani S, Asamoto M, Araki F, Chen YN, Shinokawa M, Okagami Y, Ohata T, Taguchi S, Yamada Y, Takeshima Y, Kume H, Yamada Y, Aihara M, Ito N, Fukuhara H. Prospective evaluation of visual function in patients with ocular diseases after robotic-assisted laparoscopic prostatectomy. Int J Urol. 27, 307-313, 2020. 50. Tambo M, Inoue T, Miura H, Matsuzaki J, Nutahara K, Hamamoto S, Okada S, Fukuhara H, Fujisawa M, Matsuda T. A novel flexible ureteroscope with omnidirectional bending tip using joystick-type control unit (URF-Y0016): initial validation study in bench models. J Endourol. 34, 676-681, 2020. 51. Shimizu T, Yamaguchi K, Yamamoto M, Kurioka R, Kino Y, Matsunaga W, Nakao S, Fukuhara H, Tanaka A, Gotoh A, Mabuchi M. Identification of HUHS190, a human naftopidil metabolite, as a novel anti-bladder cancer drug. Bioorganic & Medicinal Chemistry Letter 30, 126744, 2020. 52. Yoshida A, Arai Y, Hama N, Chikuta H, Bando Y, Nakano S, Kobayashi E, Shibahara J, Fukuhara H, Komiyama M, Watanabe SI, Tamura K, Kawai A, Shibata T, Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults. Histopathology 76, 509-520, 2020. 53. Taguchi S, Nakagawa T, Fukuhara H. Inconsistencies in currently used definitions of sarcopenia in oncology. Annals of Oncology 31, 318-319, 2020. 2019年 54. Nakato R, Wada Y, Nakaki R, Nagae G, Katou Y, Tsutsumi S, Nakajima N, Fukuhara H, Iguchi A, Kohro T, Kanki Y, Saito Y, Kobayashi M, Izumi-Taguchi A, Osato N, Tatsuno K, Kamio A, Hayashi-Takanaka Y, Wada H, Ohta S, Aikawa M, Nakajima H, Nakamura M, McGee RC, Heppner KW, Kawakatsu T, Genno M, Yanase H, Kume H, Senbonmatsu T, Homma Y, Nishimura S, Mitsuyama T, Aburatani H, Kimura H, Shirahige K. Comprehensive epigenome characterization reveals diverse transcriptional regulation across human vascular endothelial cells. Epigenetics Chromatin. 12, 77, 2019. 55. Taguchi S, Shiraishi K, Fujimura T, Naito A, Kawai T, Nakagawa K, Abe O, Kume H, Fukuhara H*. Robot-assisted radical prostatectomy versus volumetric modulated arc therapy: Comparison of front-line therapies for localized prostate cancer. Radiother Oncol. 140, 62-66, 2019. 56. Watanabe S, Hayashi K, Toh K, Kim HJ, Liu X, Chaya H, Fukushima S, Katsushima K, Kondo Y, Uchida S, Ogura S, Nomoto T, Takemoto H, Cabral H, Kinoh H, Tanaka HY, Kano MR, Matsumoto Y, Fukuhara H, Uchida S, Nangaku M, Osada K, Nishiyama N, Miyata K, Kataoka K. In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers. Nat Commun. 10, 1894, 2019. 57. Fujimura T, Igawa Y, Aizawa N, Niimi A, Yamada Y, Sugihara T, Kamei J, Sato Y, Matsunaga A, Yoshida M, Shinoda Y, Fukuhara H, Nakagawa T, Homma Y, Kume H. Longitudinal change of comprehensive lower urinary tract symptoms and various types of urinary incontinence during robot-assisted radical prostatectomy. Neurourol Urodyn 38, 1067-1075, 2019. 58. Akiyama Y, Daichi M, Katoh H, Morikawa T, Niimi A, Nomiya A, Sato Y, Kawai T, Goto A, Fujimura T, Fukuhara H, Nakagawa T, Igawa Y, Ishikawa S, Fukayama M, Kume H, Homma Y. Molecular Taxonomy of Interstitial Cystitis/Bladder Pain Syndrome Based on Whole Transcriptome Profiling by Next-Generation RNA Sequencing of Bladder Mucosal Biopsies. J Urol. 202, 290-300, 2019. 59. Kinjo M, Yamaguchi T, Tambo M, Okegawa T, Fukuhara H. Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder. Urol Int. 102, 331-335, 2019. 60. Taguchi S, Fukuhara H*, Todo T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.Jpn J Clin Oncol. 49, 201-209, 2019. 61. Samejima M, Taguchi S, Miyagawa S, Matsumoto R, Omura S, Ninomiya N, Nakamura Y, Yamaguchi T, Kinjo M, Tambo M, Okegawa T, Koba T, Matsuki R, Jimbo I, Motoyasu A, Tsumura T, Shimoyamada H, Shibahara J, Sakamoto Y, Fukuhara H. Acute hypotension induced by suction of cystic fluid containing extremely high concentrations of catecholamines during resection of giant pheochromocytoma. IJU Case Rep, 2, 218-220, 2019. 62. Taguchi S, Nakagawa T, Fukuhara H. Re: Jürgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol 2019. Eur Urol, S0302-2838, 30345-30348, 2019. 63. Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O; TEMPO 3:4 Investigators. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 96: 159-169. 2019 64. Higashihara E，Yamamoto K，Kaname S，Okegawa T，Tanbo M，Yamaguchi T，Shigemori K，Miyazaki I，Yokoyama K，Nutahara K：Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases. Clin Exp Nephrol. 23, 100-111, 2019. 65. Buti S，Karakiewicz PI，Bersanelli M，Capitanio U，Tian Z，Cortellini A，Taguchi S, Briganti A，Montorsi F，Leonardi F，Bandini M. Validation of the Grade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. Sci Rep. 9, 13218, 2019. 66. Fujisaki A, Kinjo M, Shimoinaba M, Honda S, Yoshimura Y. An evaluation of the impact of post-hysterectomy vesicovaginal fistula repair on the mental health of patients in a developed country. Int Urogynecol J. 2019, in press. 67. Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O; TEMPO 3:4 Investigators. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 96, 159-169, 2019. 68. Gonda K, Akama T, Nakamura T, Hashimoto E, Kyoya N, Rokkaku Y, Maejima Y, Horita S, Tachibana K, Abe N, Ohtake T, Shimomura K, Kono K, Saji S, Takenoshita S, Higashihara E. Cluster of differentiation 8 and programmed cell death ligand 1 expression in triple-negative breast cancer combined with autosomal dominant polycystic kidney disease and tuberous sclerosis complex: a case report. J Med Case Rep. 13, 381, 2019. 2018年 69. Fujimura T, Fukuhara H, Yamada Y, Taguchi S, Sugihara T, Niimi A, Nakamura M, Nakagawa T, Igawa Y, Homma Y, Kume H. Aggressive Cancer Behavior of Latent Gleason Pattern 5 in Prostatectomy Specimens. Anticancer Res. 38: 6529-6535, 2018. 70. Kinoshita Y, Sugihara T, Yasunaga H, Matsui H, Ishikawa A, Fujimura T, Fukuhara H, Ishibashi Y, Fushimi K, Homma Y. Hospital-volume effects on perioperative outcomes in peritoneal dialysis catheter implantation: analysis of 2,505 cases. Perit Dial Int. 38, 419-423, 2018. 71. Taguchi S, Fukuhara H*, Miyakawa J, Morikawa T, Naito A, Kawai T, Fujimura T, Kume H. Prognostic significance of neutrophil-to-lymphocyte ratio in collecting duct carcinoma. Jpn J Clin Oncol. 48, 692-694, 2018. 72. Otsuka M, Taguchi S, Nakagawa T, Morikawa T, Maekawa S, Miyakawa J, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Clinical significance of random bladder biopsy in primary T1 bladder cancer. Mol Clin Oncol. 8, 665-670, 2018. 73. Makino K, Nakagawa T, Ito E, Kasahara I, Murata T, Fujimura T, Fukuhara H, Homma Y. Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater. Jpn J Clin Oncol. 48, 485-49, 2018. 74. Aizawa N, Watanabe D, Fukuhara H, Fujimura T, Kume H, Homma Y, Igawa Y. Inhibitory effects of silodosin on the bladder mechanosensitive afferent activities and their relaxation with bladder myogenic contractions in male rats with bladder outlet obstruction. Neurourol Urodyn. 37, 1897-1903, 2018. 75. Akiyama Y, Niimi A, Nomiya A, Yamada Y, Nakagawa T, Fujimura T, Fukuhara H, Kume H, Igawa Y and Homma Y. Extent of Hunner lesions: the relationships with symptom severity and clinical parameters in patients with Hunner-type interstitial cystitis. Neurourol Urodyn. 37, 1441-1447, 2018. 76. Niimi A, Igawa Y, Aizawa N, Honma T, Nomiya A, Akiyama Y, Kamei J, Fujimura T, Fukuhara H and Homma Y. Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis. Neurourol Urodyn. 37, 1113-1119, 2018. 77. Yamada Y, Fujimura T, Fukuhara H, Sugihara T, Nakagawa T, Kume H, Igawa Y, Homma Y. Predictors of Early Continence after Robot-assisted Radical Prostatectomy. Low Urin Tract Symptoms. 10, 287-291, 2018. 78. Matsumoto A, Nakagawa T, Kanatani A, Ikeda M, Kawai T, Miyakawa J, Taguchi S, Naito A, Otsuka M, Nakanishi Y, Suzuki M, Koga F, Nagase Y, Kondo Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer. World J Urol. 36, 249-256, 2018. 79. Arakawa K, Hata K, Yamamoto Y, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Nozawa H, Yoshida M, Fukuhara H, Fujishiro M, Morikawa T, Yamasoba T, Koike K, Fukayama M, Watanabe T. Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum, prostate, and external ear canal-without microsatellite instability: a case report. BMC Cancer 18, 24, 2018. 80. Sato M, Taguchi A, Fukui Y, Kawata A, Taguchi S, Kashiyama T, Eguchi S, Inoue T, Tomio K, Tanikawa M, Sone K, Mori M, Nagasaka K, Adachi K, Ikemura M, Domoto Y, Arimoto T, Oda K, Fukayama M, Osuga Y, Fujii T. Blood Vessel Invasion Is a Strong Predictor of Postoperative Recurrence in Endometrial Cancer. Int J Gynecol Cancer 28, 875-881, 2018. 81. Higashihara E, Horie S, Kinoshita M, Harris PC, Okegawa T, Tanbo M, Hara H, Yamaguchi T, Shigemori K, Kawano H, Miyazaki I, Kaname S, Nutahara K. A potentially crucial role of the PKD1 C-terminal tail in renal prognosis. Clin Exp Nephrol. 22(2):395-404, 2018. 82. Okegawa T, Ninomiya N, Masuda K, Nakamura Y, Tambo M, Nutahara K. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients．Prostate. 78(8):576-582, 2018 83. Fujita N, Tambo M, Terado Y, Fujita M, Okegawa T, Nutahara K. Vesicoenteric Fistula Arising from an Adenocarcinoma of Ectopic Pancreatic Tissue in a Meckel Diverticulum. Case Rep Oncol. 4;11(1):6-10, 2018. 84. Kinjo M, Yoshimura Y, Kitagawa Y, Okegawa T, Nutahara K. Sexual activity and quality of life in Japanese pelvic organ prolapse patients after transvaginal mesh surgery. J Obstet Gynaecol Res. 44(7):1302-1307, 2018 85. Yamaguchi T, Higashihara E, Okegawa T, Miyazaki I, Nutahara K. Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan. Clin Exp Nephrol. 22(5):1213-1223, 2018. 86. Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K. Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial. Low Urin Tract Symptoms. 10, 148-151, 2018. |
| 所属学会 |
日本専門医機構（理事）、日本遺伝子治療学会（理事）、日本泌尿器内視鏡学会（理事）日本ウイルス療法学会（副理事長） 日本泌尿器科学会（代議員）、日本癌学会（評議員）、日本癌治療学会（代議員）、日本排尿機能学会（代議員）、東京医学会、日本老年泌尿器科学会、日本内視鏡外科学会、日本ミニマム創泌尿器内視鏡外科学会、米国泌尿器科学会(AUA)、国際禁制学会(ICS)、日本泌尿器腫瘍学会、日本臨床腎移植学会、泌尿器科分子・細胞研究会（評議員）、泌尿器腫瘍放射線(GUTR)研究会、日本間質性膀胱炎研究会 |
| 公的な委員会等の役員・委員歴 | 厚生労働省医師国家試験 医師試験委員 東京地方裁判所 専門委員 |
| 学外活動 | 多摩泌尿器科医会 会長 多摩女性骨盤底勉強会 代表世話人 三鷹・武蔵野・小金井 排尿障害勉強会 代表世話人 |
| ひとことメッセージ | がん治療用ウイルスを用いたウイルス療法の確立を目指しています。 患者さんに負担の少ない低浸襲性手術（ロボット支援手術、腹腔鏡下手術）を専門としています。 |
| 関連サイト | 杏林大学病院泌尿器科学教室 |